# US 2021/0172938 A1 · Assessment of preeclampsia using assays for free and dissociated placental growth factor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0172938 A1
- Document ID: US20210172938A1
- Status: Published application
- Kind: A1
- Application number: 17/119,410
- Filed: 2020-12-11
- Published: 2021-06-10
- Earliest claimed: 2019-12-04
- Assignees: Progenity, Inc.
- Applicants: Progenity, Inc.
- Inventors: Pankaj OBEROI; Sharat SINGH; Amin MAZLOOM
- Web page: https://patentgrep.com/patent/US20210172938A1

## CPC

- G01N 33/5375: {by changing the physical or chemical properties of the medium or immunochemicals, e.g. temperature, density, pH, partitioning}
- G01N 33/6863: {Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors}
- G01N 33/689: {related to pregnancy or the gonads}
- G01N 33/74: involving hormones {or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors}
- G01N 2333/471: Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
- G01N 2800/368: Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
- G01N 2800/50: Determining the risk of developing a disease
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Described herein are methods, compositions, kits, and systems for detecting free and bound PlGF, and using detection of such species to distinguish between pregnant women with or without preeclampsia or related conditions.

## Claims

### Claim at position 1

-41. (canceled)

### Claim 42

A method for determining levels of free and dissociated PlGF in a biological sample from a subject, the method comprising:
(a) isolating a first aliquot of the biological sample for the detection of PlGF-f and a second aliquot of the biological sample for the detection of PlGF-d;
(b) determining an amount of PlGF-f in the first aliquot;
(c) applying a treatment to the second aliquot to dissociate PlGF complexes; and
(d) determining an amount of PlGF-d in the second aliquot.

### Claim 43 (depends on 42)

The method of claim 42, further comprising determining a ratio of the amounts of PlGF-f and PlGF-d.

### Claim 44 (depends on 42)

The method of claim 42, wherein the biological sample has not been stored at a temperature above about 20° C.

### Claim 45 (depends on 42)

The method of ay claim 42, wherein the amount of PlGF-f and the amount of PlGF-d are determined using same reagents.

### Claim 46 (depends on 42)

The method of claim 42, wherein the PlGF complex comprises PlGF and s-FLT.

### Claim 47 (depends on 42)

The method of claim 42, wherein the treatment is applied for at least 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, or 120 minutes.

### Claim 48 (depends on 42)

The method of claim 42, wherein the treatment comprises increasing the temperature of the second portion of the biological sample.

### Claim 49 (depends on 48)

The method of claim 48, wherein the treatment comprises increasing the temperature to at least 30° C. for at least 1 hour.

### Claim 50 (depends on 42)

The method of claim 42, wherein the treatment comprises increasing or decreasing the pH of the second portion of the biological sample.

### Claim 51 (depends on 42)

The method of claim 42, wherein the treatment comprises contacting the second portion of the biological sample with an agent that prevents PlGF from assembling into a PlGF complex or disables PlGF from a PlGF:sFLT1 complex.

### Claim 52 (depends on 51)

The method of claim 51, wherein the agent is selected from: a surfactant, a detergent, a chaotropic agent, a PlGF-binding protein, and an s-FLT-binding protein.

### Claim 53 (depends on 42)

The method of claim 42, wherein the method has a LLOQ for PlGF of 20 pg/ml or less.

### Claim 54

(canceled)

### Claim 55

(canceled)

### Claim 56

(canceled)

### Claim 57

(canceled)

### Claim 58

(canceled)

### Claim 59 (depends on 42)

The method of claim 42, wherein the biological sample is blood, serum, plasma, amniotic fluid, or urine.

### Claim 60 (depends on 42)

The method of claim 42, wherein the biological sample is serum or plasma.

### Claim 61 (depends on 42)

The method of claim 42, where the biological sample is collected from a pregnant human female.

### Claim 62 (depends on 61)

The method of claim 61, wherein the pregnant human female has been pregnant for at least 20 weeks.

### Claim 63 (depends on 62)

The method of claim 62, wherein the pregnant human female has been pregnant for no more than 30 weeks.

### Claim at position 24

-96. (canceled)

### Claim 97 (depends on 42)

The method of claim 42, wherein the amount of PlGF-f, PlGF-d, or both is determined by an immunoassay.

### Claim 98 (depends on 97)

The method of claim 97, wherein the immunoassay is selected from a capture ELISA, an indirect ELISA, a TR-FRET assay, a proximity extension assay, an amplified luminescent proximity (LOCI) assay, an electrochemiluminescence immunoassay, a luminescent oxygen channeling assay, or a lateral flow assay.

### Claim 99 (depends on 42)

The method of claim 42, wherein (b) or (d) involve contacting the first aliquot, second aliquot, or both with a capture reagent.

### Claim 100 (depends on 99)

The method of claim 99, wherein the capture agent comprises an antibody or an antigen-binding fragment thereof.
